Similar articles

• Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet-activating factor receptor antagonist.

  Herbert JM, Bernat A, Valette G, Gigo V, Lale A, LaPlace MC, Lespy L, Savi P, Maffrand JP, Le Fur G. Herbert JM, et al. J Pharmacol Exp Ther. 1991 Oct;259(1):44-51. J Pharmacol Exp Ther. 1991. PMID: 1656029
• [Effect of analogs and antagonists of the thrombocyte-activating factor (PAF) on blood platelet aggregation].

  Lakin KM, Kulikov VI, Manevich EM, Muliar AG, Shvets VI. Lakin KM, et al. Farmakol Toksikol. 1988 Jul-Aug;51(4):113-23. Farmakol Toksikol. 1988. PMID: 2847936 Review. Russian. No abstract available.
• Effects of Ro 24-4736 in antagonizing the platelet and bronchoconstrictor responses to PAF.

  O'Donnell M. O'Donnell M. Ann N Y Acad Sci. 1991;629:416-8. doi: 10.1111/j.1749-6632.1991.tb38002.x. Ann N Y Acad Sci. 1991. PMID: 1659287 No abstract available.
• Hypersensitivity of diabetic human platelets to platelet activating factor.

  Shukla SD, Paul A, Klachko DM. Shukla SD, et al. Thromb Res. 1992 May 1;66(2-3):239-46. doi: 10.1016/0049-3848(92)90194-f. Thromb Res. 1992. PMID: 1329254
• Preclinical and clinical pharmacology of platelet-activating factor receptor antagonists.

  Handley DA. Handley DA. Med Res Rev. 1990 Jul-Sep;10(3):351-70. doi: 10.1002/med.2610100304. Med Res Rev. 1990. PMID: 2164623 Review. No abstract available.